Drug intelligence / Profile preview

Chymonom

Development stage: Unknown
Lead developer: Acinom Healthcare
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

**Chymonom** is an oral fixed-dose proteolytic enzyme product marketed by Acinom Healthcare. Each tablet is labeled as containing trypsin-chymotrypsin with total activity of 100,000 Armour units. It is marketed for reducing swelling and supporting recovery following injury or surgery, including postoperative inflammatory swelling. The enzymes promote proteolysis of inflammatory protein deposits, including fibrin, which may aid edema resolution, clearance of damaged tissue debris, and tissue repair. ([acinomhealthcare.com](https://www.acinomhealthcare.com/product/trypsin-chymotrypsin-100000-au/))

Brand names: Chymonom
Other names: trypsin + chymotrypsintrypsin-chymotrypsin

Targets

Fibrin (Factor Ia)

Beyond the preview

Go deeper on Chymonom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chymonom.

Explore the full profile